Ross Moat joins us as a Consultant Advisor to the Board of Trustees in a voluntary capacity and brings with him over 15 years’ experience in commercial and business development in biotech and pharmaceuticals in Europe.
Ross has held various positions within this industry including executive roles and has lead drug launches and managed sales growth across portfolios of drugs in rare diseases, palliative care, oncology and urology. He has in-depth knowledge on medicinal and therapeutic drugs for both common and rare diseases.
Ross has already represented the AADC Trust at meetings and provided essential feedback and advice to our board of Trustees on several pharmaceutical and disease related issues. Navigating this space is intricate and new to the AADC Trust following arrival of two pioneering AAV2-hAADC gene replacement therapies which have the potential to improve the symptoms of our patient population. Having Ross onboard and sharing in our passion to finding a cure for this deadly disease, will only strengthen our understanding in this complicated rare disease space.
We are extremely thankful to have his wealth of knowledge and experience and look forward to a long and rewarding relationship.